Importance of Complete Skin Clearance in Psoriasis as a Treatment Goal: Implications for Patient-Reported Outcomes

被引:13
作者
Blauvelt, Andrew [1 ]
Wu, Jashin J. [2 ]
Armstrong, April [3 ]
Menter, Alan [4 ]
Liu, Clive [5 ]
Jacobson, Abby [6 ]
机构
[1] Oregon Med Res Ctr, Portland, OR 97223 USA
[2] Dermatol Res & Educ Fdn, Irvine, CA USA
[3] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA
[4] Baylor Scott & White, Div Dermatol, Dallas, TX USA
[5] Bellevue Dermatol, Bellevue, WA USA
[6] Ortho Dermatol, Bridgewater, NJ USA
关键词
TO-SEVERE PSORIASIS; LONG-TERM EFFICACY; AORTIC VASCULAR INFLAMMATION; SEVERE PLAQUE PSORIASIS; FACTOR-ALPHA INHIBITORS; QUALITY-OF-LIFE; PHASE-III; MYOCARDIAL-INFARCTION; MONOCLONAL-ANTIBODY; NATIONAL PSORIASIS;
D O I
10.36849/JDD.2020.4957
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Psoriasis is associated with physical, psychological, social, and economic burdens that lead to substantial impairment over a patient's lifetime. It is important to understand how different skin clearance levels may relate to patient perceptions of psoriasis symptoms and health-related quality of life. Here, we highlight notable advantages to complete skin clearance relative to high levels of efficacy without complete skin clearance, including meaningful improvements in patient-reported signs and symptoms of psoriasis, a higher mean proportion of symptom-free days, and significant improvements in quality of life. We also review biologic therapies associated with high percentages of complete skin clearance and significant improvements in signs and symptoms of psoriasis, notably brodalumab. These therapies are likely to play important roles in the future treatment of moderate-to-severe psoriasis, given that improvement in quality of life is of significant value relative to biologics or other systemic therapies associated with lower rates of complete skin clearance.
引用
收藏
页码:487 / 492
页数:6
相关论文
共 64 条
  • [1] Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey
    Armstrong, A.
    Jarvis, S.
    Boehncke, W. -H.
    Rajagopalan, M.
    Fernandez-Penas, P.
    Romiti, R.
    Bewley, A.
    Vaid, B.
    Huneault, L.
    Fox, T.
    Sodha, M.
    Warren, R. B.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (12) : 2200 - 2207
  • [2] Armstrong A, 2019, FALL CLIN DERM C OCT
  • [3] Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies
    Armstrong, April W.
    Reich, Kristian
    Foley, Peter
    Han, Chenglong
    Song, Michael
    Shen, Yaung-Kaung
    You, Yin
    Papp, Kim A.
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (01) : 155 - 164
  • [4] From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis
    Armstrong, April W.
    Siegel, Michael P.
    Bagel, Jerry
    Boh, Erin E.
    Buell, Megan
    Cooper, Kevin D.
    Duffin, Kristina Callis
    Eichenfield, Lawrence F.
    Garg, Amit
    Gelfand, Joel M.
    Gottlieb, Alice B.
    Koo, John Y. M.
    Korman, Neil J.
    Krueger, Gerald G.
    Lebwohl, Mark G.
    Leonardi, Craig L.
    Mandelin, Arthur M.
    Menter, M. Alan
    Merola, Joseph F.
    Pariser, David M.
    Prussick, Ronald B.
    Ryan, Caitriona
    Shah, Kara N.
    Weinberg, Jeffrey M.
    Williams, MaryJane O. U.
    Wu, Jashin J.
    Yamauchi, Paul S.
    Van Voorhees, Abby S.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (02) : 290 - 298
  • [5] Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States Findings From the National Psoriasis Foundation Surveys, 2003-2011
    Armstrong, April W.
    Robertson, Andrew D.
    Wu, Julie
    Schupp, Clayton
    Lebwohl, Mark G.
    [J]. JAMA DERMATOLOGY, 2013, 149 (10) : 1180 - 1185
  • [6] Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5years of treatment (SCULPTURE Extension Study)
    Bissonnette, R.
    Luger, T.
    Thaci, D.
    Toth, D.
    Lacombe, A.
    Xia, S.
    Mazur, R.
    Patekar, M.
    Charef, P.
    Milutinovic, M.
    Leonardi, C.
    Mrowietz, U.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (09) : 1507 - 1514
  • [7] Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study
    Bissonnette, R.
    Luger, T.
    Thaci, D.
    Toth, D.
    Messina, I.
    You, R.
    Guana, A.
    Fox, T.
    Papavassilis, C.
    Gilloteau, I.
    Mrowietz, U.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (04) : 1033 - 1042
  • [8] Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations
    Blauvelt, A.
    Griffiths, C. E. M.
    Lebwohl, M.
    Mrowietz, U.
    Puig, L.
    Ball, S.
    Zhang, L.
    Edson-Heredia, E.
    Warner, M.
    Zhu, B.
    Lin, C-Y.
    Nikai, E.
    Dey, D.
    Mallbris, L.
    Reich, K.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (02) : 587 - 590
  • [9] Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and-3)
    Blauvelt, Andrew
    Papp, Kim A.
    Griffiths, Christopher E. M.
    Puig, Luis
    Weisman, Jamie
    Dutronc, Yves
    Kerr, Lisa Farmer
    Ilo, Dapo
    Mallbris, Lotus
    Augustin, Matthias
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2017, 18 (02) : 273 - 280
  • [10] Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
    Blauvelt, Andrew
    Papp, Kim A.
    Griffiths, Christopher E. M.
    Randazzo, Bruce
    Wasfi, Yasmine
    Shen, Yaung-Kaung
    Li, Shu
    Kimball, Alexa B.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (03) : 405 - 417